Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

May Validate Small Molecule Platform

 
• By Andrew McConaghie
  
Sanofi Lyon
Sanofi already has an anti-inflammation blockbuster in Dupixent, experience which could help bring C4X Discovery's candidate to market.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip